Offer vaginal oestrogen to women with urogenital atrophy (including those on systemic HRT) and continue treatment for as long as needed to relieve symptoms.
Consider vaginal oestrogen for women with urogenital atrophy in whom systemic HRT is contraindicated, after seeking advice from a healthcare professional with expertise in menopause.
If vaginal oestrogen does not relieve symptoms of urogenital atrophy, consider increasing the dose after seeking advice from a healthcare professional with expertise in menopause.
Explain to women with urogenital atrophy that:
- Symptoms often come back when treatment is stopped
- Adverse effects from vaginal oestrogen are very rare
- They should report unscheduled vaginal bleeding to their GP
Do not offer routine monitoring of endometrial thickness during treatment for urogenital atrophy.